Terug
63
31
Ook genoteerd als
ESALF
OTC
Dagbereik
€ 7,54
€ 7,64
52-Weeksbereik
€ 5,94
€ 9,22
Volume
4.900
50D / 200D Gem.
€ 7,56
/
€ 7,52
Vorige Slotkoers
€ 7,52
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 0,2 | 0,3 |
| P/B | 0,0 | 2,9 |
| ROE % | 5,4 | 3,7 |
| Net Margin % | 5,9 | 3,8 |
| Rev Growth 5Y % | 5,1 | 10,0 |
| D/E | 0,2 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2027 |
€ 39,14
€ 37,47 – € 40,69
|
870 B | 1 |
| FY2026 |
€ 40,70
€ 38,97 – € 42,31
|
860 B | 1 |
Belangrijkste Punten
Revenue grew 5,14% annually over 5 years — modest growth
Debt/Equity of 0,22 — conservative balance sheet
Generating 7,15B in free cash flow
P/E of 0,19 — trading at a low valuation
Capital efficient — spends only 2,91% of revenue on capex
ROIC of 3,96% — low return on invested capital
Groei
Revenue Growth (5Y)
5,14%
Revenue (1Y)6,42%
Earnings (1Y)9,49%
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
5,41%
ROIC3,96%
Net Margin5,88%
Op. Margin6,89%
Veiligheid
Debt / Equity
0,22
Current Ratio1,95
Interest Coverage15,45
Waardering
P/E Ratio
0,19
P/B Ratio0,01
EV/EBITDA-1,28
Dividend Yield0,04%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 6,42% | Revenue Growth (3Y) | 2,98% |
| Earnings Growth (1Y) | 9,49% | Earnings Growth (3Y) | -8,48% |
| Revenue Growth (5Y) | 5,14% | Earnings Growth (5Y) | 2,58% |
| Profitability | |||
| Revenue (TTM) | 789,40B | Net Income (TTM) | 46,43B |
| ROE | 5,41% | ROA | 3,35% |
| Gross Margin | 78,62% | Operating Margin | 6,89% |
| Net Margin | 5,88% | Free Cash Flow (TTM) | 7,15B |
| ROIC | 3,96% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,22 | Current Ratio | 1,95 |
| Interest Coverage | 15,45 | Dividend Yield | 0,04% |
| Valuation | |||
| P/E Ratio | 0,19 | P/B Ratio | 0,01 |
| P/S Ratio | 0,01 | PEG Ratio | 2,36 |
| EV/EBITDA | -1,28 | Dividend Yield | 0,04% |
| Market Cap | 8,66B | Enterprise Value | -69,38B |
Income Statement
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 789,40B | 741,75B | 744,40B | 756,23B | 645,94B |
| Net Income | 46,43B | 42,41B | 55,43B | 47,95B | 41,94B |
| EPS (Diluted) | 40,94 | 36,97 | 48,33 | 41,81 | 36,73 |
| Gross Profit | 620,59B | 586,42B | 566,57B | 581,40B | 484,63B |
| Operating Income | 54,38B | 53,41B | 40,04B | 53,75B | 53,22B |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 1,39T | 1,39T | 1,26T | 1,24T | 1,09T |
| Total Liabilities | 520,58B | 494,82B | 440,78B | 467,78B | 362,07B |
| Shareholders' Equity | 841,42B | 875,61B | 799,96B | 748,82B | 703,18B |
| Total Debt | 187,52B | 159,41B | 126,11B | 94,89B | 89,89B |
| Cash & Equivalents | 265,56B | 304,68B | 267,35B | 309,63B | 248,74B |
| Current Assets | 727,66B | 722,98B | 622,20B | 640,61B | 518,34B |
| Current Liabilities | 372,29B | 304,47B | 298,95B | 313,33B | 256,02B |
Strategiescores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
#105 of 827
#314 of 709
Recente Activiteit
Ingestapt
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt
Defensive Investing (Benjamin Graham)
Mar 24, 2026